Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hMaxi-K Gene Transfer for Erectile Dysfunction
NCT02713789Phase 2Completed
- Sponsor
- Urovant Sciences
- Start
- Apr 2015
- Primary completion
- Aug 2017
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of hMaxi-K in erectile dysfunction (ED) (3 arms), sponsored by Urovant Sciences. Primary endpoints: Erectile Function Domain of the International Index of Erectile Function at 24 weeks, Sexual Encounter Profile Question 2 at 24 weeks and 4 more. Started Apr 2015; status: completed.
02
Drugs
hMaxi-K
03
Conditions
erectile dysfunction (ED)
Beyond the preview
Go deeper on NCT02713789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02713789.